IMO from a business perspective, I can’t think of many bigger mistakes than to delay the start of other trials to wait on the FA for BoM. According to clinicaltrials.gov the 2a CKD trial for people on dialysis is still set to start next week. What if BoM was to fail the FA but Apabetalone was to prove to be a lifesaving drug for those with CKD, why delay the trial further.

From a shareholder perspective I would much prefer to see all realistic potential for all compounds at RVX being explored in a timely fashion that way one failure does not have as big an impact on the overall business. I know we are all probably pretty happy about the last few days but to me one of the biggest failings of management has been the inability to adequately fund the business to not only explore the full potential of Apabetalone but to also get moving on the 6 or 7 other “clinic ready” compounds that allegedly have great potential.

I am happy with the events of the last few days but there still needs to be a lot more business accomplished before I will be referring to the business management of this company as anything better than mediocre.  We were lucky when Eastern found us and stepped in and I think compelling science not good business has carried the day ever since. I think now the opportunity to do some real business is greater than it has ever been, I hope management can step way up to the challenge. JMO